BioNexus Gene Lab (BGLC) Net Income towards Common Stockholders (2018 - 2026)

BioNexus Gene Lab has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$543575.0 for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$543575.0, up 12.79% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 37.16% YoY), and the FY2025 annual result was -$3.0 million, down 86.73% from the prior year.
• Net Income towards Common Stockholders came in at -$543575.0 for Q1 2026 at BioNexus Gene Lab, up from -$1.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $351515.0 in Q4 2023 to a low of -$2.6 million in Q3 2023.
• The 5-year median for Net Income towards Common Stockholders is -$291231.0 (2023), against an average of -$468462.4.
• Peak annual rise in Net Income towards Common Stockholders reached 771.48% in 2023, while the deepest fall reached 3271.0% in 2023.
• BioNexus Gene Lab's Net Income towards Common Stockholders stood at -$52349.0 in 2022, then surged by 771.48% to $351515.0 in 2023, then sank by 199.09% to -$348319.0 in 2024, then plunged by 197.46% to -$1.0 million in 2025, then surged by 47.54% to -$543575.0 in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$543575.0 (Q1 2026), -$1.0 million (Q4 2025), and -$708991.0 (Q3 2025), per Business Quant data.